

Figure 1




Figure 2




Figure 3

Figure 3A



EWS-FLI



Figure 3B




NIH3T3



E-F Zyxine



AS-Zyxine



Actin filament

zyxin

BEST AVAILABLE COPY

Figure 4




Figure 5




Figure 6






Figure 7

A




B



BEST AVAILABLE COPY

Figure 8



BEST AVAILABLE COPY

Figure 9




Figure 10





Figure 11






Figure 12A




Figure 12B

Figure 12C

**BEST AVAILABLE COPY**

NIH3T3 cells transfected by the oncogene EWS-FIi treated with 10 and 100 nM of jasplakinolide



Figure 12D



Figure 12E

NIH3T3 cells transfected by the oncogene EWS-FIi treated with 10 and 20 nM of dolastatin 11



Figure 12F




Figure 12G

BEST AVAILABLE COPY

Figure 13A1




Figure 13A2




Figure 13B1




Figure 13B2




Figure 14





Figure 15



PHARMACEUTICAL COMPOSITION FOR....


Inventors: Christian Auclair et al.

EMC: EL 978573765 US


Sheet 17 of 17

Docket No. 1417-03

Piper Rudnick LLP (215) 656-3381



**Figure 16A.** : Chemical formula of dolastatin 11



**Fig16B.** : Chemical structure of jasplakinolide